Form 4: Mirum Director Sells Shares After Option Exercise

Mirum Pharmaceuticals Director Saira Ramasastry exercised stock options and immediately sold the resulting common stock under a pre-arranged 10b5-1 plan.

Summary

• Director Saira Ramasastry exercised 2,000 stock options at an exercise price of $23.51 per share on March 16, 2026.
• Concurrently, Ramasastry sold 2,000 shares of Mirum Pharmaceuticals common stock at a price of $90.76 per share on the same date.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025.
• Following these transactions, Ramasastry's direct beneficial ownership of common stock is 0 shares, while 4,000 stock options remain beneficially owned.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While a director sale can sometimes be seen negatively, the execution under a 10b5-1 plan makes it a routine liquidity event rather than a signal of changing sentiment towards the company's prospects.

Positives

• The sale was executed at a significantly higher price ($90.76) than the exercise price ($23.51), indicating a substantial personal gain for the director.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which provides an affirmative defense against insider trading allegations and demonstrates planned liquidity management.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, potentially raising questions about insider confidence.
• The director's direct beneficial ownership of common stock is now 0 following the sale, although stock options are still held.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by the market. While a 10b5-1 plan provides a legal framework for such sales, the market often interprets director sales as a potential signal, regardless of the pre-planned nature. This transaction is a routine part of executive compensation and liquidity management.

Stakeholder Impact

• Shareholders: May observe the director's sale, potentially leading to questions about insider confidence, though the 10b5-1 plan mitigates this concern.
• Employees: No direct impact from this specific transaction.
• Management: The transaction reflects a director's personal financial planning rather than a corporate strategic move.

Key Dates

Recommendation

The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which is a common practice for executives managing personal finances. It does not provide new fundamental information about Mirum Pharmaceuticals' operational performance or future prospects that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on the company's underlying business fundamentals.

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Director Transaction, Saira Ramasastry, 10b5-1 Plan